Covid-19 roundup: Teamed up with NIH, Re­gen­eron launch­es PhI­II pre­ven­tion tri­al for an­ti­body cock­tail

As Re­gen­eron moves its an­ti­body cock­tail in­to Phase II/III tri­als test­ing REGN-COV2 as a treat­ment for both hos­pi­tal­ized and non-hos­pi­tal­ized pa­tients with Covid-19, the biotech is al­so start­ing a Phase III in the pre­ven­tion set­ting.

The Na­tion­al In­sti­tute of Al­ler­gy and In­fec­tious Dis­eases — which or­ches­trat­ed the large, ran­dom­ized study for remde­sivir that pro­duced pos­i­tive re­sults — will joint­ly run the study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.